Express News | Adaptimmune Therapeutics: Entered Mutual Release and Resolution Agreement With Genentech Inc & F. Hoffmann-La Roche Ltd
Adaptimmune to Participate in Two Bank Conferences This September
Individual Investors Who Own 39% Along With Institutions Invested in Adaptimmune Therapeutics Plc (NASDAQ:ADAP) Saw Increase in Their Holdings Value Last Week
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Monday Trading
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Open Week Strong Monday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
Adaptimmune Therapeutics (NASDAQ:ADAP) Investors Are Sitting on a Loss of 74% If They Invested Three Years Ago
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright analyst Arthur He CFA maintains $Adaptimmune Therapeutics(ADAP.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate
HC Wainwright & Co. Reiterates Buy on Adaptimmune Therapeutics, Maintains $4 Price Target
Adaptimmune Therapeutics Analyst Ratings
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading
Leerink Partners Maintains Adaptimmune Therapeutics(ADAP.US) With Hold Rating, Maintains Target Price $2
Leerink Partners analyst Jonathan Chang maintains $Adaptimmune Therapeutics(ADAP.US)$ with a hold rating, and maintains the target price at $2.According to TipRanks data, the analyst has a success
Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.15
Scotiabank analyst George Farmer maintains $Adaptimmune Therapeutics(ADAP.US)$ with a buy rating, and maintains the target price at $3.15.According to TipRanks data, the analyst has a success rate
A Quick Look at Today's Ratings for Adaptimmune Therapeutics(ADAP.US), With a Forecast Between $1 to $4
On Aug 13, major Wall Street analysts update their ratings for $Adaptimmune Therapeutics(ADAP.US)$, with price targets ranging from $1 to $4.Barclays analyst Peter Lawson maintains with a sell rating,
Scotiabank Sticks to Its Buy Rating for Adaptimmune Therapeutics (ADAP)
Buy Rating Affirmed for Adaptimmune Therapeutics Amidst Promising Product Launch and Strong Pipeline
Adaptimmune Therapeutics: A Cautious Hold Amid Gradual Launch and Long-Term Growth Strategy